
















SYSTEMATIC REVIEW

**REVISED** Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis [version 2; peer review: 2 approved]

Endang Mutiawati <sup>1,2</sup>, Syahrul Syahrul <sup>1,2</sup>, Marhami Fahriani <sup>3</sup>, Jonny Karunia Fajar <sup>3,4</sup>, Sukamto S. Mamada <sup>5</sup>, Helnida Anggun Maliga<sup>6</sup>, Nur Samsu<sup>4</sup>, Muhammad Ilmawan <sup>6</sup>, Yeni Purnamasari <sup>6</sup>, Annisa Ayu Asmiragani<sup>6</sup>, Ichsan Ichsan <sup>3,7</sup>, Talha Bin Emran <sup>8</sup>, Ali A. Rabaan <sup>9</sup>, Sri Masyeni <sup>10,11</sup>, Firzan Nainu <sup>5</sup>, Harapan Harapan <sup>3,7,12</sup>



- <sup>1</sup>Department of Neurology, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
- <sup>2</sup>Department of Neurology, Dr. Zainoel Abidin Hospital, Banda Aceh, Aceh, 23126, Indonesia
- <sup>3</sup>Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia
- <sup>4</sup>Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia
- <sup>5</sup>Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi, 90245, Indonesia
- <sup>6</sup>Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65117, Indonesia
- <sup>7</sup>Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia
- <sup>8</sup>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh
- <sup>9</sup>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia
- <sup>10</sup>Department of Internal Medicine, Faculty of Medicine and Health Sciences, Universitas Warmadewa, Denpasar, Bali, 80235, Indonesia
- <sup>11</sup>Department of Internal Medicine, Sanjiwani Hospital, Denpasar, Bali, 80235, Indonesia
- <sup>12</sup>Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia







**v2** First published: 12 Nov 2020, 9:1316  
<https://doi.org/10.12688/f1000research.27334.1>  
 Latest published: 10 Mar 2021, 9:1316  
<https://doi.org/10.12688/f1000research.27334.2>


**Abstract**

**Background:** This study was conducted to determine the prevalence of headache in coronavirus disease 2019 (COVID-19) and to assess its association as a predictor for COVID-19. This study also aimed to discuss the possible pathogenesis of headache in COVID-19.  
**Methods:** Available articles from PubMed, Scopus, and Web of Science were searched as of September 2<sup>nd</sup>, 2020. Data on characteristics of the study, headache and COVID-19 were extracted following the PRISMA guidelines. Biases were assessed using the Newcastle-Ottawa scale. The cumulative prevalence of headache was calculated for the general population (i.e. adults and children). The pooled odd ratio (OR) with 95% confidence intervals (95%CI) was calculated using the Z test to assess the association between headache and the presence of COVID-19 cases.

**Open Peer Review**

**Reviewer Status**  

	Invited Reviewers	
	1	2
<b>version 2</b> (revision) 10 Mar 2021	 report	 report
<b>version 1</b> 12 Nov 2020	  report	  report

1. **Erni J. Nelwan** , University of Indonesia, Jakarta, Indonesia


**Results:** We included 104,751 COVID-19 cases from 78 eligible studies to calculate the global prevalence of headache in COVID-19 and 17 studies were included to calculate the association of headache and COVID-19. The cumulative prevalence of headache in COVID-19 was 25.2% (26,464 out of 104,751 cases). Headache was found to be more prevalent, approximately by two-fold, in COVID-19 patients than in non-COVID-19 patients (other respiratory viral infections), OR: 1.73; 95% CI: 1.94, 2.5 with  $p=0.04$ .

**Conclusion:** Headache is common among COVID-19 patients and seems to be more common in COVID-19 patients compared to those with the non-COVID-19 viral infection. No definitive mechanisms on how headache emerges in COVID-19 patients but several possible hypotheses have been proposed. However, extensive studies are warranted to elucidate the mechanisms.

**PROSPERO registration:** [CRD42020210332](https://www.crd.org/CRD42020210332) (28/09/2020)


### Keywords

COVID-19, SARS-CoV-2, headache, severity, predictor



This article is included in the [Disease Outbreaks gateway](#).

Universitas Indonesia, Depok City, Indonesia

2. **Morteza Arab-Zozani** , Birjand University of Medical Sciences, Birjand, Iran

Any reports and responses or comments on the article can be found at the end of the article.

**Corresponding author:** Endang Mutiawati ([endangmutiawati@unsyah.ac.id](mailto:endangmutiawati@unsyah.ac.id))

**Author roles:** **Mutiawati E:** Conceptualization, Resources, Validation, Writing – Original Draft Preparation; **Syahrul S:** Resources, Validation, Writing – Review & Editing; **Fahriani M:** Data Curation, Investigation, Methodology, Software, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Fajar JK:** Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Writing – Review & Editing; **Mamada SS:** Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Maliga HA:** Investigation, Methodology, Validation; **Samsu N:** Data Curation, Formal Analysis, Investigation, Validation; **Ilmawan M:** Data Curation, Formal Analysis, Investigation, Validation; **Purnamasari Y:** Data Curation, Formal Analysis, Investigation, Validation; **Asmiragani AA:** Data Curation, Formal Analysis, Investigation, Validation; **Ichsan I:** Writing – Review & Editing; **Emran TB:** Writing – Original Draft Preparation, Writing – Review & Editing; **Rabaan AA:** Writing – Review & Editing; **Masyeni S:** Writing – Review & Editing; **Nainu F:** Writing – Original Draft Preparation, Writing – Review & Editing; **Harapan H:** Conceptualization, Data Curation, Investigation, Methodology, Resources, Software, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2021 Mutiawati E *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Mutiawati E, Syahrul S, Fahriani M *et al.* **Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis [version 2; peer review: 2 approved]** F1000Research 2021, 9:1316 <https://doi.org/10.12688/f1000research.27334.2>

**First published:** 12 Nov 2020, 9:1316 <https://doi.org/10.12688/f1000research.27334.1>

**REVISED Amendments from Version 1**

In the new version we have revised some parts:

1. We have provided clearer explanation what “non-COVID-19 patients” means in abstract, methods and results section. For example in Data synthesis subheading we added “non-COVID-19 cases (other respiratory viral infections such as rhinovirus, influenza, parainfluenza and respiratory syncytial virus).”
2. We have provided the approach how to solve in case there was discrepancies between two authors during evaluation of the studies.
3. We have provided more detail information of Newcastle-Ottawa scale (NOS) - What items that were assessed and how to score as well how the studies classified. We also have added the NOS scores briefly to all studies included in the study.
4. We have included the limitation of the data and the analysis in particular inability to do sub-analyses based on COVID-19 severity, the existence of COVID-19 co-morbidity and demographic characteristics due to scarcity of the available data. We added “In this analysis we did not analyze the prevalence of headache based on COVID-19 severity, the existence of COVID-19 co-morbidity (such as diabetes and hypertension) and based on demographic characteristics such as gender due to scarcity of the available data. Therefore, whenever enough data are available, such sub-analyses are critical to be conducted.”

**Any further responses from the reviewers can be found at the end of the article**

## Introduction

The current coronavirus disease 2019 (COVID-19) pandemic has caused a global crisis for both the health and economic sectors. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is a member of the *Coronavirinae* family and Betacoronavirus subfamily together with severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle Eastern respiratory syndrome coronavirus (MERS-CoV)<sup>1</sup>. The virus is primarily transmitted from person-to-person through droplets from symptomatic and pre-symptomatic patients, and is likely to also be transmitted by asymptomatic individuals<sup>2-6</sup>. Currently, no effective vaccines or pharmaceutical agents against SARS-CoV-2 are available but some progressions have been made to produce vaccines and drugs against the disease<sup>7-10</sup>.

Although up to 20.3% of hospitalized patients require admission to the intensive care unit (ICU)<sup>11</sup> with complications such as hypoxemia, acute respiratory distress syndrome (ARDS), arrhythmia, shock, acute cardiac injury, and acute kidney injury<sup>12-14</sup>, most SARS-CoV-2 infections are asymptomatic or have mild symptoms<sup>1,15,16</sup>. The common clinical symptoms of COVID-19 include fever, dry cough, dyspnea, chest pain, fatigue and myalgia<sup>1,12,17,18</sup>. In some cases, other neurological manifestations such as headache, dizziness, seizure, taste and smell impairment were also reported<sup>12,18-21</sup>. Headache is one of the symptoms that is also reported in various viral infections such as dengue and chikungunya that are common in the tropical regions<sup>22,23</sup> and therefore may not be specific for COVID-19.

In addition, the prevalence of headache in COVID-19 patients varies across studies<sup>19,20,24</sup>. A study found that the prevalence of headache was 17.4% (94/540) in Hubei province, the epicenter of the outbreak, and 14.1% (111/788) among patients outside the epicenter<sup>21</sup>. Another study in European countries found that the headache was reported in more than 40% of 417 COVID-19 patients<sup>19</sup>. Furthermore, the association of headache with the presence of COVID-19 is unknown. This systematic review was undertaken to provide robust evidence on the prevalence of headache in COVID-19 patients globally and its association with COVID-19 cases. Information described in this study might help clinicians to decide whether headache could be used as one of the basic symptoms to be included in diagnosing SARS-CoV-2 infection, especially those in the front line with limited resources.

## Methods

### Registration and protocol

This systematic review was conducted as recommended by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines<sup>25</sup>. The protocol of this study was registered with PROSPERO, an international database of prospectively registered systematic reviews at the University of York, on 28<sup>th</sup> September 2020 (CRD42020210332).

### Eligibility criteria of studies

Articles reporting headache as a symptom of COVID-19 cases were included. COVID-19 cases should be diagnosed with RT-PCR test using either nasopharyngeal and oropharyngeal swab, bronchoalveolar lavage or cerebrospinal fluid (CSF). All cross-sectional and cohort studies that included COVID-19 cases randomly selected from the population were considered eligible while case reports and case series including all editorials, reviews, and commentaries were excluded. Case-control studies with pre-allocated number of patients with headache and non-headache were excluded. Studies that were conducted in specific populations only such as in pregnancy, children, cancer patients and other groups were excluded. Only articles written in English were included in this study.

### Information sources and search strategy

To identify potential articles for analysis, systematic searches were conducted using three bibliographical databases (PubMed, Scopus, and Web of Science) as of September 2<sup>nd</sup>, 2020. The search criteria were as follows. PubMed ([Title] “SARS-CoV-2” OR “COVID-19” OR “Wuhan coronavirus” OR “Wuhan virus” OR “novel coronavirus” OR “nCoV” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus disease 2019 virus” OR “2019-nCoV” OR “2019 novel coronavirus” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus” OR “coronaviruses” OR “SARS 2” OR “2019-nCoV acute respiratory disease” OR “novel coronavirus pneumonia” OR “COVID”) AND ([All] “Headache”). Scopus ([Title] “SARS-CoV-2” OR “COVID-19” OR “Wuhan coronavirus” OR “Wuhan virus” OR “novel coronavirus” OR “nCoV” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus disease 2019 virus” OR “2019-nCoV” OR “2019 novel coronavirus” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus” OR

“coronaviruses” OR “SARS 2” OR “2019-nCoV acute respiratory disease” OR “novel coronavirus pneumonia” OR “COVID”) AND ([All] “Headache”). Web of Science ([Title] “SARS-CoV-2” OR “COVID-19” OR “Wuhan coronavirus” OR “Wuhan virus” OR “novel coronavirus” OR “nCoV” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus disease 2019 virus” OR “2019-nCoV” OR “2019 novel coronavirus” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus” OR “coronaviruses” OR “SARS 2” OR “2019-nCoV acute respiratory disease” OR “novel coronavirus pneumonia” OR “COVID”) AND ([All] “Headache”). English as language limitation was imposed in the searches. Only peer-reviewed articles were included. Data were extracted both from the articles and the supplementary materials. Reference lists from the eligible articles were retrieved for further relevant studies.

### Study selection

All titles and abstracts of identified articles were imported into the EndNote X9 (Thompson Reuters, Philadelphia, PA, USA) and duplicate records between databases were removed. Retrieved articles were initially screened based on title and abstract to identify possible eligible studies. The full texts of potentially eligible articles were then reviewed. The screening and review processes were conducted by two authors (MF and JKF). After reviewing the full texts, the eligibility of each study was decided. Any discrepancies between the two authors were solved by consulting with another investigator (HH).

### Data extraction

The following data were extracted from eligible articles: study characteristics (author, title, journal, study site and study design), headache characteristics (number of patients with headache, type of headache, localization, and severity), COVID-19 characteristics (number of patients with COVID-19, severity, and outcome).

### Role of the funding source

This study received no external funding.

### Outcomes

The primary outcomes of this systematic review were: a) the prevalence of headache in COVID-19 cases; and b) the association between headache and COVID-19 cases compared to other viral infections.

### Data synthesis

The cumulative prevalence rate of headache was calculated for COVID-19 cases in the general population. The prevalence was calculated as the number of COVID-19 cases with headache divided by the total number of COVID-19 cases with and without headache, expressed as a percentage (%). Pooled odd ratios (OR) and 95% confidence intervals (95% CI) were calculated to assess the association of headache and COVID-19 compared to non-COVID-19 cases (other respiratory viral infections such as rhinovirus, influenza, parainfluenza and respiratory syncytial virus).

### Risk of bias assessment

To reduce sample selection bias, a critical assessment was specifically conducted in terms of setting of study and diagnosis

of COVID-19. The quality of eligible studies was assessed using critical appraisals based on the Newcastle-Ottawa scale (NOS)<sup>26</sup>. This scale evaluates 9 criteria of the study including the sample selection (4 items), group comparison (1 item), and the outcome (3 items). The scores range between 0 to 9 in which classified into three groups: low ( $\leq 4$ ), moderate (between 5–6), and high quality study ( $\geq 7$ ).

### Statistical analysis

The association between headache and the presence of COVID-19 was assessed by the calculation of a pooled OR and 95%CI using the Z test ( $p < 0.05$  was considered statistically significant). Prior to analysis, gathered data from studies were evaluated for heterogeneity and potential publication bias. Heterogeneity among studies was assessed using the Q test. Initial analysis found that the data had heterogeneity ( $p < 0.10$ ) and therefore a random effect model was employed. Egger’s test and a funnel plot were used to assess the reporting or publication bias ( $p < 0.05$  was considered having potential for publication bias). The data were analyzed using **Review Manager** version 5.3<sup>27</sup>. The cumulative pooled OR and 95%CI was presented in a forest plot.


## Results

### Study eligibility results

The literature searches yielded 732 articles, of which 229 were excluded as duplicates between databases. Following a screening process of the titles and abstracts of the remaining 503 articles, an additional 253 articles were excluded due to irrelevant studies leaving 250 articles (Figure 1). The full texts of the remaining 250 articles were retrieved and screened for eligibility. This process excluded additional 49 articles that were not eligible as they did not fulfill the inclusion criteria. A full assessment was conducted on 201 articles. All included studies had high quality with NOS score  $\geq 7$ .

To calculate the prevalence of headache in COVID-19, full-text assessment resulted in the exclusion of 123 articles for the following reasons: case control studies ( $n=2$ ), case report studies ( $n=69$ ), case series ( $n=29$ ), duplicated dataset ( $n=1$ ), and conducted in specific population only ( $n=23$ ). The targeted population studies were conducted among healthcare workers<sup>28–31</sup>, diabetic patients<sup>32</sup>, pediatrics<sup>33</sup>, pregnant women<sup>34</sup>, cancer patients<sup>35</sup>, children and young adults<sup>36–40</sup>, patient undergone surgery<sup>41</sup>, critical patients<sup>42</sup>, women undergone delivery<sup>43</sup>, patients with mild-moderate COVID-19<sup>44–46</sup>, patients with gastrointestinal symptoms<sup>47</sup>, patients with severe headache only<sup>48</sup>, and patients with anosmia only<sup>49</sup>. In total, 78 studies were included to calculate the prevalence of headache in COVID-19 and all studies were published in 2020. The studies were conducted in Brazil<sup>50</sup>, China<sup>13,51–96</sup>, Egypt<sup>97</sup>, France<sup>98–101</sup>, Germany<sup>102</sup>, India<sup>103,104</sup>, Italy<sup>105–111</sup>, Japan<sup>112,113</sup>, Jordan<sup>114</sup>, Somalia<sup>115</sup>, South Korea<sup>116,117</sup>, Spain<sup>118,119</sup>, Turkey<sup>120,121</sup>, and the US<sup>122–126</sup>. Two studies were cross-sectional<sup>119,122</sup>, five were prospective cohort studies<sup>65,90,98,110,121</sup> and the remaining 71 studies were retrospective studies.

To calculate the association between headache and COVID-19, the full-text assessment yielded 16 eligible studies. The rest of the references had been excluded for these reasons: (a) the studies were case reports or case-series ( $n=98$ ); (b) the full-text did not include data of outcome of interest ( $n=84$ ); and



**Figure 1.** Flowchart of the result of literature search according to the preferred reporting items of systematic reviews and meta-analyses (PRISMA).

(c) low quality of study (n=3) (Figure 1). The included studies were conducted in a wide ranges of regions: Australia<sup>127</sup>, Belgium<sup>29</sup>, Brazil<sup>50</sup>, China<sup>70</sup>, France<sup>99</sup>, Hongkong<sup>128</sup>, Israel<sup>129</sup>, Italy<sup>130</sup>, Germany<sup>131</sup>, Netherlands<sup>31</sup>, Turkey<sup>120</sup>, and the US<sup>28,105,122,132,133</sup>. Out of the studies, ten were case-control<sup>28,29,31,99,105,120,128,130,132</sup>, four were cross-sectional<sup>50,70,122,131,133</sup>, and two were prospective cohort studies<sup>127,129</sup>.

### The prevalence of headache in COVID-19 cases

Our systematic review included 78 studies consisting of 104,751 COVID-19 patients and headache was reported in 26,464

patients with a cumulative prevalence of 25.26%. The list of the studies and the prevalence of headache of each study is presented in Table 1. One study which included 51 patients described the specific location of headache: 1.96% (1/51) was a temporal headache, 35.29% (18/51) was a frontal headache, 23.52% (12/51) was a retro-orbital headache, and 39.21% (20/51) was a diffuse headache<sup>99</sup>. Another study which involved 46 patients reported that 40 (86%) had tension-type pain and 6 (14%) had migraine-like headache<sup>107</sup>. Data from 18 studies indicated that 72.17% (236/327) of headaches were reported in mild-moderate COVID-19 cases<sup>51,53,55-58,62,63,67,76,88,92-97,117</sup>. The



**Table 1. Characteristic of eligible studies and the prevalence of headache in each study.**

No	Country	Study design	Total headache	Total population	Headache Percentage	Reference
1	Japan	Retrospective	7	57	12.3	112
2	Italy	Retrospective	10	213	4.7	105
3	China	Retrospective	4	72	5.6	51
4	USA	Cross sectional	39	59	66.1	122
5	China	Retrospective	6	83	7.2	52
6	Italy	Retrospective	11	70	15.7	106
7	China	Retrospective	17	262	6.5	53
8	USA	Retrospective	24,308	91,412	26.6	123
9	Egypt	Retrospective	18	66	27.3	97
10	India	Retrospective	34	522	6.5	103
11	China	Retrospective	2	14	14.3	54
12	China	Retrospective	5	50	10.0	55
13	India	Retrospective	3	21	14.3	104
14	China	Retrospective	3	36	8.3	56
15	China	Retrospective	2	20	10.0	57
16	China	Retrospective	19	189	10.1	58
17	China	Retrospective	3	37	8.1	59
18	South Korea	Retrospective	54	172	31.4	116
19	China	Retrospective	12	67	17.9	60
20	China	Retrospective	13	137	9.5	61
21	China	Retrospective	14	204	6.9	62
22	China	Retrospective	17	221	7.7	63
23	China	Retrospective	4	85	4.7	64
24	France	Prospective	99	197	50.2	98
25	France	Retrospective	51	70	72.9	99
26	China	Prospective	3	38	7.9	65
27	China	Retrospective	21	62	33.9	66
28	China	Retrospective	12	202	5.9	67
29	USA	Retrospective	72	251	28.7	124
30	China	Retrospective	9	85	10.6	68
31	China	Retrospective	75	788	9.5	69
32	Jordan	Retrospective	14	81	17.3	114
33	China	Retrospective	3	34	8.8	70
34	Japan	Retrospective	2	23	8.7	113
35	China	Retrospective	8	72	11.1	71
36	China	Retrospective	14	108	13.0	72
37	Italy	Retrospective	46	108	42.6	107
38	China	Retrospective	2	11	18.2	73
39	China	Retrospective	8	51	15.7	74

No	Country	Study design	Total headache	Total population	Headache Percentage	Reference
40	China	Retrospective	8	99	8.1	13
41	China	Retrospective	12	136	8.8	75
42	South Korea	Retrospective	140	694	20.2	117
43	China	Retrospective	5	48	10.4	76
44	China	Retrospective	4	28	14.3	77
45	China	Retrospective	14	53	26.4	78
46	China	Retrospective	11	125	8.8	79
47	China	Retrospective	67	651	10.3	80
48	China	Retrospective	98	1084	9.0	81
49	China	Retrospective	6	59	10.2	82
50	Spain	Retrospective	137	576	23.8	118
51	Spain	Cross sectional	104	576	18.1	119
52	France	Retrospective	82	139	59.0	100
53	China	Retrospective	21	270	7.8	83
54	China	Retrospective	80	655	12.2	84
55	China	Retrospective	2	33	6.1	85
56	Brazil	Retrospective	76	145	52.4	50
57	China	Retrospective	9	136	6.6	86
58	China	Retrospective	10	60	16.7	87
59	Somalia	Retrospective	10	60	16.7	115
60	Italy	Retrospective	2	10	20.0	108
61	Turkey	Retrospective	43	143	30.1	120
62	Germany	Retrospective	63	108	58.3	102
63	France	Retrospective	10	64	15.6	101
64	China	Retrospective	28	214	13.1	88
65	USA	Retrospective	129	208	62.0	125
66	Italy	Retrospective	30	72	41.7	109
67	Italy	Prospective	14	43	32.6	110
68	China	Retrospective	4	24	16.7	89
69	Turkey	Prospective	64	239	26.8	121
70	China	Prospective	3	8	37.5	90
71	China	Retrospective	35	187	18.7	91
72	China	Retrospective	5	93	5.4	92
73	China	Retrospective	3	29	10.3	93
74	China	Retrospective	1	108	0.9	94
75	China	Retrospective	20	663	3.0	95
76	USA	Retrospective	40	200	20.0	126
77	Italy	Retrospective	16	72	22.2	111
78	China	Retrospective	14	389	3.6	96
Total			26,464	104,751	25.2	

prevalence of headache in severe COVID-19 cases from 15 studies was 27.83% (86/309)<sup>53,55,57,58,62,63,73,76,88,92,93,95–97,117</sup>.

### Association of headache and COVID-19

A total of 16 studies, consisting of 5,407 COVID-19 cases in adults and 94,818 adults with non-COVID-19 infections (mostly COVID-19-like respiratory viral infections), were analyzed to determine the association between headache and COVID-19. Of these studies, an association between headache and the occurrence of COVID-19 was observed in 9 studies<sup>28,29,31,105,122,127,129,130,132</sup> while seven studies reported no association<sup>50,70,99,120,131,133,134</sup> (Table 2). Our cumulative calculation revealed that headache was found to be 1.7-fold more prevalent in patients with COVID-19 compared to those with non-COVID-19 respiratory viral infections, OR: 1.73; 95% CI: 1.94, 2.51 with  $p=0.04$ . The correlation between headache and COVID-19 is presented in Figure 2.

## Discussion

### Headache and COVID-19

As a non-specific symptom, headache might present not only in COVID-19 cases but also in other viral diseases, therefore, headache might not raise suspicion of SARS-CoV-2 infection<sup>22,23</sup>. However, a study described that headache is one of the main neurological symptoms of coronavirus infection including SARS-CoV-2<sup>135</sup>. The global prevalence of headache in our systematic review is more than 25% out of 104,751 COVID-19 cases. This result was almost double that of the previously reported prevalence from studies in China early in the pandemic that ranged from 6.5–13.1%<sup>53,88</sup>. This suggests that headache is prevalent in SARS-CoV-2 infection and therefore could potentially be used as one of the indicators to diagnose COVID-19 cases. In this analysis we did not analyze the prevalence of headache based on COVID-19 severity, the existence of COVID-19 co-morbidity (such as diabetes and hypertension) and based on demographic characteristics such as gender due to scarcity of the available data. Therefore, whenever enough data are available, such sub-analyses are critical to be conducted.

Our study also highlights that headache was significantly more prevalent in COVID-19 patients, 2.2-fold, than suspected non-COVID-19 viral infection (other respiratory viral infections). A study found that only around 11% of MERS patients reported they suffered from headaches<sup>136</sup>. A study in COVID-19 patients with pre-existing primary headache disorders revealed that the headache during COVID-19 had an unusual presentation with 42% (44/104) reporting a recent onset of headaches, 49% (51/104) had a change in headache pattern, and 39% (39/104) reported the worst headache they had ever had<sup>119</sup>. These results suggest that new onset headache and changes of headache pattern should be carefully explored as this might be able to differentiate patients with COVID-19 from those without.

### Headache pathogenesis in COVID-19

We explored the available literature to broaden our knowledge of the pathogenesis of headache in COVID-19. In general, three main primary headaches are observed in COVID-19

patients i.e. migraine, cluster headache and tension-type headache<sup>137–140</sup>. No fixed mechanisms have been reported on how these headaches emerge in COVID-19 patients. However, it has been proposed that the activation of trigeminal nerve ending in the periphery followed by the sensitization of various sites in the brain is one of the main pathomechanism of headache in these patients<sup>137,138</sup>.

A headache attack is initiated by the release of several vasoactive neuropeptides such as glutamate, calcitonin gene-related peptide (CGRP), substance P and pituitary adenylate cyclase-activating polypeptide (PACAP), from nociceptive sensory fibers (especially nociceptive C-fibers and A $\delta$ -fibers) innervating blood vessels located in the meninges and other cranial structures leading to vasodilation, degranulation of mast cells and plasma protein extravasation in those vascular structures<sup>141–143</sup>. The release of those peptides from the fibers could be due to either electrical, chemical or mechanical induction emerged from three branches of the trigeminal nerve i.e. ophthalmic, maxillary and mandibular branches<sup>143</sup>. However, because of its wider area of innervation in the meninges and cranial blood vessels, ophthalmic branch seems to play more of a role in stimulating nociceptive processes in meningeal structures than the other two branches<sup>143,144</sup>.

Next, any physiological events, such as vasodilation, that have occurred in the meningeal and large cerebral blood vessels will become a stimulus which is sent to the trigeminal ganglion (TG) where other nociceptive information from other afferent trigeminal branches are also converging<sup>141</sup>. Although cerebral and meningeal vasodilation is not the sole cause of headache<sup>145</sup>, most studies have agreed on the critical role of blood vessel dilation in the emergence of headaches.

From the TG, the stimulus is projected to an area in the brainstem called the trigeminocervical complex (TCC) via first-order neurons<sup>143</sup>. These transmissions are then projected to the diencephalon structures, including the thalamus and hypothalamus, via the second-order neurons<sup>143,146</sup>. The third-order neurons are subsequently responsible for transmitting the information from diencephalic systems to various cortical areas associated with motoric, somatosensory, auditory, retrosplenial and visual functions<sup>141,143</sup>, leading to the manifestation of headache pain and other related symptoms (Figure 3).

During these transmission processes, the release of neuropeptides, especially CGRP, is limited only in the meninges and in the central terminals of trigeminal afferents<sup>147</sup>. When the transmission reaches TCC structures, CGRP and substance P may act to induce the release of glutamate and reduce gamma aminobutyric acid (GABA) production<sup>147,148</sup>. It has been proposed that during a headache attack, the level of glutamate in the TCC increases, while GABA release is decreased<sup>148</sup>. This condition could result in the increase of nociceptive neurons excitability<sup>149</sup>. Moreover, low level of serotonin in trigeminal nerve might also be involved in migraine pathophysiology as the release of this neurotransmitter has been linked to the inhibition of CGRP in trigeminal nerves<sup>150,151</sup>.



**Table 2. Prevalence of headache in COVID-19 and non-COVID-19.**

Author, year	Study type	COVID-19		Non-COVID-19		COVID-19 severity	Control criteria	Reference
		Headache n (%)	Sample size	Headache n (%)	Sample size			
Çalica Utku <i>et al.</i> , 2020	Case control	43 (0.30)	143	42 (0.27)	154	Mild-critical	Viral symptoms, negative PCR	120
Caturegli <i>et al.</i> , 2020	Case control	17 (0.28)	60	5 (0.09)	55	Not specified	Viral symptoms, negative PCR	132
Fistera <i>et al.</i> , 2020	Cross-sectional	5 (0.12)	43	21 (0.08)	271	Not specified	Viral symptoms, negative PCR	131
He <i>et al.</i> , 2020	Cross-sectional	3 (0.09)	34	5 (0.10)	48	Not specified	Viral symptoms, negative PCR	13
Ibrahim <i>et al.</i> , 2020	Cohort	3 (0.75)	4	22 (0.05)	429	Not specified	Viral symptoms, negative PCR	127
Kosugi <i>et al.</i> , 2020	Cross sectional	76 (0.52)	145	20 (0.53)	38	Not specified	Viral symptoms, negative PCR	50
La Torre <i>et al.</i> , 2020	Case control	18 (0.60)	30	14 (0.19)	75	Not specified	Viral symptoms, negative PCR	130
Lam <i>et al.</i> , 2020	Case control	0 (0.00)	37	7 (0.06)	111	Not specified	Viral symptoms, negative PCR	128
Lan <i>et al.</i> , 2020	Case control	34 (0.41)	83	141 (0.28)	509	Not specified	Viral symptoms, negative PCR	28
Luigetti <i>et al.</i> , 2020	Case control	10 (0.05)	213	1 (0.00)	218	Not specified	Viral symptoms, negative PCR	105
Mizrahi <i>et al.</i> , 2020	Cohort	126 (3.09)	4066	2794 (3.05)	91597	Not specified	Viral symptoms, negative PCR	129
Rolan <i>et al.</i> , 2020	Cross-sectional	93 (0.64)	145	90 (0.57)	157	Not specified	Viral symptoms, negative PCR	133
Tostmann <i>et al.</i> , 2020	Case control	64 (0.71)	90	296 (0.42)	713	Mild	COVID symptoms, negative PCR	31
Van Loon <i>et al.</i> , 2020	case control	145 (0.62)	185	116 (0.78)	186	Mild	Viral symptoms, negative PCR	29
Yan <i>et al.</i> , 2020	Cross-sectional	39 (0.66)	59	99 (0.49)	203	Not specified	Viral symptoms, negative PCR	122
Zayet <i>et al.</i> , 2020	Case control	51 (0.73)	70	31 (0.57)	54	Not specified	Confirmed influenza A/B	99




Figure 2. Forest plot of the correlation between headache and the prevalence of COVID-19.




Figure 3. Proposed pathway of headache pathophysiology. Nociceptive information coming from peripheral networks is transmitted to trigeminal ganglion acting as central hub between peripheral and central nervous systems. Next, this information is sent to TCC located in the brainstem, transmitted to diencephalon structures and terminated in various areas in cortex. The transmission in this pathway is linked to the pivotal involvement of neurotransmitters (e.g. glutamate, GABA and serotonin) and nociceptive neuropeptides (e.g. CGRP, substance P and PACAP) released from nerve fibers synapses, particularly nociceptive C-fibers and Aδ-fibers. The receptors of these signaling molecules are identified in both peripheral blood vessel, trigeminal ganglion and central structures, such as in cerebrospinal fluid and TCC<sup>142,147</sup>.

Several mechanisms have been postulated to explain how trigeminovascular system is activated in COVID-19. Firstly, direct invasion of the virus may activate the peripheral trigeminal system<sup>137</sup>. This theory is hypothesized according to a study, confirming that trigeminal ganglia possess an angiotensinergic activity<sup>152</sup>. Thus, the viral attack would hypothetically disturb the activity of the renin-angiotensin-aldosterone system (RAAS), which may increase the level of CGRP<sup>153</sup>. Although the invasion of SARS-CoV-2 into the olfactory nerve ending seems to be the main route<sup>154-156</sup>, the action of the virus on the trigeminal nerve must not be overlooked, as suggested by Perlman *et al.* (1989). They demonstrated that the trigeminal nerve, in addition to the olfactory nerve, was a route used by neurotropic murine coronavirus to invade the central nervous system (CNS)<sup>157</sup>. The hypothesis of trigeminal nerve attack by SARS-CoV-2 is also supported by the fact that olfactory mucosa is innervated by the trigeminal nerve<sup>158,159</sup> suggesting the invasion of the olfactory mucosa by SARS-CoV-2 may also induce trigeminal nerve injury.

Following entry into the trigeminal nerve, SARS-CoV-2 may hijack the transneuronal transport system to direct the virus to enter the nucleus via a retrograde axonal transport mechanism. This transport occurs by the involvement of cytoskeletal motor proteins called dynein supported by cofactor dynactin that function to move substances, such as endosomes and vesicles, including hijacking viruses, on microtubule towards the cell body<sup>160</sup>. Once the virus gains access to the nucleus in the cell body through the microtubule-organizing center (MTOC), viral replication is initiated<sup>161</sup>. Finally, viral progenies may spread to other areas of the body, including the CNS, via anterograde axonal transport assisted by the kinesin motor protein family<sup>160</sup>.

A study suggested a transneuronal transport system used by coronavirus after investigating the neuroinvasiveness of HCoV-OC43 in mice<sup>162</sup>. Furthermore, the movement of SARS-CoV-2 via retrograde axonal transport is also hypothesized as it has been reported that the envelope protein of SARS-CoV could subvert dynein function either directly or indirectly<sup>163</sup>. The role of dynein in the retrograde axonal movement of several viruses, such as herpesviruses, West Nile virus, rabies, and influenza virus, upon their penetration in the neuronal plasma membrane has also been reported<sup>164-169</sup>.

Secondly, SARS-CoV-2 may also invade the trigeminal nerve by indirect mechanisms. Cytokine storm and vasculopathy mechanisms are also proposed to explain the activation of trigeminal nerve upon SARS-CoV-2 infection<sup>137</sup>. Cytokine storm has attracted substantial interest from researchers and clinicians as this unwanted condition is strongly suggested to be related to the increased mortality in SARS-CoV-2-infected patients<sup>170,171</sup>. It is hypothesized that the headache suffered by COVID-19 patients at the later stage of this infection is induced by the cytokine storm<sup>139,172,173</sup>. This notion has been supported by the fact that proinflammatory cytokines, such as IL-1, IL-6 and TNF- $\alpha$ , have been linked to the activation of the trigeminovascular

system, which is responsible for the emergence and development of headache through the modulation of CGRP<sup>174-177</sup>.

Moreover, the presence of angiotensin-converting enzyme 2 (ACE2) receptor on the endothelial cells makes the blood vessels vulnerable to invasion by SARS-CoV-2<sup>178,179</sup>. It is known that ACE2 is associated with several protective mechanisms within the body, such as vasodilation<sup>180</sup> and antinociception<sup>181</sup>. ACE2 also diminishes excessive free radical production which prevents oxidative stress<sup>182</sup>. The utilization of this receptor by the virus may decrease its activities, leading to the disturbance of vascular function. The perivascular trigeminal nerve may in turn be affected resulting in the COVID-19-related headache<sup>137</sup>. More studies are required to improve our understanding on the role of the ACE2 receptor in headache pathophysiology.

Another hypothesis by which SARS-CoV-2 could induce headache is offered by Abboud *et al.* (2020). They proposed that gas exchange disturbance in alveolar tissues triggered by the viruses would induce hypoxia, which in turn leads to ischemia<sup>170,183</sup>. Ischemia itself has been known to have a strong relation with headache incidents<sup>184</sup> that could be induced by exaggerating the production of free radicals.

In regards to the headache characteristics presented by COVID-19 patients compared to the headache induced by other viral infections, no apparent differences could be observed. Headache in COVID-19 could be worsened by physical or head movement, felt in either the entire head (holocranial) or unilaterally (hemicranial) and the pain is typically pressing or tightening<sup>139</sup>. It is hypothesized that headaches occurring in COVID-19 patients might be the result of the same mechanisms as observed in influenza A and influenza B infections, which could be related to the activity of cytokines<sup>173,185-187</sup>. A recent report on dengue-related headache suggested that the headache could be pulsating and either affect the entire brain, only frontal, or orbital area, which may resemble primary headaches reported in COVID-19 patients<sup>139,172,188</sup>. Therefore, although we found that headache is more frequent in COVID-19 patients than those of non-COVID-19 patients, diagnosis of COVID-19 should not be based on the presence of a headache.

In conclusion, headache is a common symptom in COVID-19 cases. Some mechanisms have been proposed as to the mechanism for headaches in COVID-19 such as the activation of the trigeminovascular system by either direct action of the virus or indirect mechanisms induced by cytokine storm, vasculopathy, or ischemia induced by gas exchange disturbance in COVID-19 patients. Extensive efforts must be carried out to provide definitive answers about COVID-19-related headaches. Detailed investigations on the mechanisms by which SARS-CoV-2 attacks the CNS and thus generates headaches are important to improve our understanding on the pathophysiology of COVID-19, and therefore influences possible pharmacological intervention decisions.

## Data availability

### Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

### Reporting guidelines

Figshare: PRISMA checklist for ‘Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis’, <https://doi.org/10.6084/m9.figshare.13166783.v1><sup>189</sup>

Data are available under the terms of the [Creative Commons Attribution 4.0 International license \(CC-BY 4.0\)](https://creativecommons.org/licenses/by/4.0/).

### Acknowledgement

Authors would like to thank HT Editorial Services in assisting during the study and writing processes.

## References

- Harapan H, Itoh N, Yufika A, et al.: **Coronavirus disease 2019 (COVID-19): A literature review.** *J Infect Public Health.* 2020; **13**(5): 667–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhao H, Lu X, Deng Y, et al.: **COVID-19: asymptomatic carrier transmission is an underestimated problem.** *Epidemiol Infect.* 2020; **148**: e116. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lu D, Sang L, Du S, et al.: **Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission.** *J Med Virol.* 2020; **92**(9): 1660–1664. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Huff HV, Singh A: **Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies.** *Clin Infect Dis.* 2020; **ciaa654**. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bai Y, Yao L, Wei T, et al.: **Presumed Asymptomatic Carrier Transmission of COVID-19.** *JAMA.* 2020; **323**(14): 1406–1407. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gandhi M, Yokoe DS, Havlir DV: **Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19.** *N Engl J Med.* 2020; **382**(22): 2158–60. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frediansyah A, Nainu F, Dhama K, et al.: **Remdesivir and its antiviral activity against COVID-19: A systematic review.** *Clin Epidemiol Glob Health.* 2020; In press. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frediansyah A, Tiwari R, Sharun K, et al.: **Antivirals for COVID-19: A critical review.** *Clin Epidemiol Glob Health.* 2020; (In press). [Publisher Full Text](#)
- Keam S, Megawati D, Patel SK, et al.: **Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.** *Rev Med Virol.* 2020; **30**(5): e2123. (In press). [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sharun K, Tiwari R, Yatoo M, et al.: **Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.** *Expert Opin Biol Ther.* 2020; **20**(9): 1033–1046. (In press). [PubMed Abstract](#) | [Publisher Full Text](#)
- Dhama K, Khan S, Tiwari R, et al.: **Coronavirus Disease 2019-COVID-19.** *Clin Microbiol Rev.* 2020; **33**(4): e00028–20. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Huang C, Wang Y, Li X, et al.: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020; **395**(10223): 497–506. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chen N, Zhou M, Dong X, et al.: **Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.** *Lancet.* 2020; **395**(10223): 507–13. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Patel SK, Singh R, Rana J, et al.: **The kidney and COVID-19 patients - Important considerations.** *Travel Med Infect Dis.* 2020; **37**: 101831. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Richardson S, Hirsch JS, Narasimhan M, et al.: **Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.** *JAMA.* 2020; **323**(20): 2052–2059. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wu Z, McGoogan JM: **Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.** *JAMA.* 2020; **323**(13): 1239–42. [PubMed Abstract](#) | [Publisher Full Text](#)
- Li Z, Wang Y, Zhu J, et al.: **Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona.** *J Control Release.* 2020; **320**: 1–18. [PubMed Abstract](#) | [Publisher Full Text](#)
- Wang D, Hu B, Hu C, et al.: **Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.** *JAMA.* 2020; **323**(11): 1061–1069. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lechien JR, Chiesa-Estomba CM, De Siaty DR, et al.: **Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.** *Eur Arch Otorhinolaryngol.* 2020; **277**(8): 2251–2261. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kim ES, Chin BS, Kang CK, et al.: **Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19.** *J Korean Med Sci.* 2020; **35**(13): e142. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Liang WH, Guan WJ, Li CC, et al.: **Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China.** *Eur Respir J.* 2020; **55**(6): 2000562. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Harapan H, Michie A, Sasmono RT, et al.: **Dengue: A Minireview.** *Viruses.* 2020; **12**(8): 829. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Harapan H, Michie A, Mudatsir M, et al.: **Chikungunya virus infection in Indonesia: a systematic review and evolutionary analysis.** *BMC Infect Dis.* 2019; **19**(1): 243. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ma C, Su S, Wang J, et al.: **From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.** *Microbes Infect.* 2020; **22**(6–7): 245–253. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Moher D, Liberati A, Tetzlaff J, et al.: **Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.** *Plos Med.* 2009; **6**(7): e1000097. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stang A: **Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.** *Eur J Epidemiol.* 2010; **25**(9): 603–5. [PubMed Abstract](#) | [Publisher Full Text](#)
- Training Cochrane: **Review Manager (RevMan) 5.3.** Copenhagen: The Nordic Cochrane Centre. 2008; 373. [Reference Source](#)
- Lan FY, Fuller R, Mathew S, et al.: **COVID-19 symptoms predictive of healthcare workers’ SARS-CoV-2 PCR results.** *PLoS One.* 2020; **15**(6): e0235460. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Van Loon N, Verbrugge M, Cartuyvels R, et al.: **Diagnosis of COVID-19 Based on Symptomatic Analysis of Hospital Healthcare Workers in Belgium: Observational Study in a Large Belgian Tertiary Care Center during Early COVID-19 Outbreak.** *J Occup Environ Med.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
- Korth J, Wilde B, Dolff S, et al.: **SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.** *J Clin Virol.* 2020; **128**: 104437. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tostmann A, Bradley J, Bousema T, et al.: **Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.** *Euro Surveill.* 2020; **25**(16): 2000508. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)



32. Wang F, Yang Y, Dong K, *et al.*: **Clinical Characteristics of 28 Patients with Diabetes and Covid-19 in Wuhan, China.** *Endocr Pract.* 2020; **26**(6): 668–74. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Sun D, Li H, Lu XX, *et al.*: **Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study.** *World J Pediatr.* 2020; **16**(3): 251–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Diouf AA, Mbaye KD, Gueye M, *et al.*: **Clinical characteristics and outcomes of COVID-19 infection in nine pregnant women: A report from a Sub-Saharan African Country, Senegal.** *Pan African Medical Journal.* 2020; **35**(2): 58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Pinato DJ, Lee AJX, Biello F, *et al.*: **Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.** *Cancers (Basel).* 2020; **12**(7): 1841. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Xiong X, Chua GT, Chi S, *et al.*: **A Comparison Between Chinese Children Infected with Coronavirus Disease-2019 and with Severe Acute Respiratory Syndrome 2003.** *J Pediatr.* 2020; **224**: 30–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Mahmoudi S, Mehdizadeh M, Sherwin Badv R, *et al.*: **The Coronavirus Disease 2019 (COVID-19) in Children: A Study in an Iranian Children's Referral Hospital.** *Infect Drug Resist.* 2020; **13**: 2649–55. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Blumfield E, Levin TL, Kurian J, *et al.*: **Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19.** *AJR Am J Roentgenol.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
39. Abdel-Mannan O, Eyre M, Lobel U, *et al.*: **Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children.** *JAMA Neurol.* 2020; e202687. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. DeBiasi RL, Song X, Delaney M, *et al.*: **Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region.** *J Pediatr.* 2020; **223**: 199–203.e1. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Peng S, Huang L, Zhao B, *et al.*: **Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.** *J Thorac Cardiovasc Surg.* 2020; **160**(2): 585–92.e2. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Wang ZH, Shu C, Ran X, *et al.*: **Critically Ill Patients with Coronavirus Disease 2019 in a Designated ICU: Clinical Features and Predictors for Mortality.** *Risk Manag Healthc Policy.* 2020; **13**: 833–45. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Fassett MJ, Lurvey LD, Yasumura L, *et al.*: **Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization.** *Am J Perinatol.* 2020; **37**(11): 1110–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Lechien JR, Chiesa-Estomba CM, Place S, *et al.*: **Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019.** *J Intern Med.* 2020; **288**(3): 335–44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Lechien JR, Chiesa-Estomba CM, Cabaraux P, *et al.*: **Features of Mild-to-Moderate COVID-19 Patients With Dysphonia.** *J Voice.* 2020; S0892-1997(20)30183-1. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Barillari MR, Bastiani L, Lechien JR, *et al.*: **A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study.** *J Med Virol.* 2020; **12**. [PubMed Abstract](#) | [Publisher Full Text](#)
47. Chen YW, Yiu CPB, Wong KY: **Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 2; peer review: 3 approved].** *F1000Res.* 2020; **9**: 129. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Guillmot A, Maldonado S, Slootjes S, Sellimi A, *et al.*: **Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.** *J Neurol.* 2020; **1–7**. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Naeini AS, Karimi-Galoughi M, Raad N, *et al.*: **Paranasal sinuses computed tomography findings in anosmia of COVID-19.** *Am J Otolaryngol.* 2020; **41**(6): 102636. [PubMed Abstract](#) | [Publisher Full Text](#)
50. Kosugi EM, Lavinsky J, Romano FR, *et al.*: **Incomplete and late recovery of sudden olfactory dysfunction in COVID-19.** *Braz J Otorhinolaryngol.* 2020; **86**(4): 490–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Liu Z, Jin C, Wu CC, *et al.*: **Association between Initial Chest CT or Clinical Features and Clinical Course in Patients with Coronavirus Disease 2019 Pneumonia.** *Korean J Radiol.* 2020; **21**(6): 736–45. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Devaux CA, Rolain JM, Colson P, *et al.*: **New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?** *Int J Antimicrob Agents.* 2020; **55**(5): 105938. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Tian S, Hu N, Lou J, *et al.*: **Characteristics of COVID-19 infection in Beijing.** *J Infect.* 2020; **80**(4): 401–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Lei P, Huang Z, Liu G, *et al.*: **Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?** *J Xray Sci Technol.* 2020; **28**(3): 369–81. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Xu YH, Dong JH, An WM, *et al.*: **Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2.** *J Infect.* 2020; **80**(4): 394–400. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Qiu H, Wu J, Hong L, *et al.*: **Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.** *Lancet Infect Dis.* 2020; **20**(6): 689–96. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Chen G, Wu D, Guo W, *et al.*: **Clinical and immunological features of severe and moderate coronavirus disease 2019.** *J Clin Invest.* 2020; **130**(5): 2620–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Wang Y, Luo S, Zhou CS, *et al.*: **Clinical and radiological characteristics of COVID-19: a multicenter, retrospective, observational study.** *Hong Kong Med J.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
59. Tian S, Chang Z, Wang Y, *et al.*: **Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China.** *Front Med (Lausanne).* 2020; **7**: 210. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Du W, Yu J, Wang H, *et al.*: **Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China.** *Infection.* 2020; **48**(3): 445–52. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Liu K, Fang YY, Deng Y, *et al.*: **Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.** *Chin Med J (Engl).* 2020; **133**(9): 1025–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. He R, Lu Z, Zhang L, *et al.*: **The clinical course and its correlated immune status in COVID-19 pneumonia.** *J Clin Virol.* 2020; **127**: 104361. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Zhang G, Hu C, Luo L, *et al.*: **Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.** *J Clin Virol.* 2020; **127**: 104364. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Du Y, Tu L, Zhu P, *et al.*: **Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.** *Am J Respir Crit Care Med.* 2020; **201**(11): 1372–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Huang C, Wang Y, Li X, *et al.*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet.* 2020; **395**(10223): 497–506. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Xu XW, Wu XX, Jiang XG, *et al.*: **Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.** *BMJ.* 2020; **368**: m606. at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Epub 2020/02/23. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Huang R, Zhu L, Xue L, *et al.*: **Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study.** *PLoS Negl Trop Dis.* 2020; **14**(5): e0008280. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Liu Z, Ding L, Chen G, *et al.*: **Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China.** *Front Med (Lausanne).* 2020; **7**: 209. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Lian JS, Cai H, Hao SR, *et al.*: **Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure history in Zhejiang Province, China.** *J Zhejiang Univ Sci B.* 2020; **21**(5): 369–77. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. He JL, Luo L, Luo ZD, *et al.*: **Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China.** *Respir Med.* 2020; **168**: 105980. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Ding X, Yu Y, Lu B, *et al.*: **Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.** *Clin Chem Lab Med.* 2020; **58**(8): 1365–71. [PubMed Abstract](#) | [Publisher Full Text](#)
72. Han R, Huang L, Jiang H, *et al.*: **Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia.** *AJR Am J Roentgenol.* 2020; **215**(2): 338–43. [PubMed Abstract](#) | [Publisher Full Text](#)
73. Dong X, Cao YY, Lu XX, *et al.*: **Eleven faces of coronavirus disease 2019.** *Allergy.* 2020; **75**(7): 1699–709. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)



74. Song F, Shi N, Shan F, et al.: **Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia**. *Radiology*. 2020; **295**(1): 210–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Chen P, Zhang Y, Wen Y, et al.: **Epidemiological and clinical characteristics of 136 cases of COVID-19 in main district of Chongqing**. *J Formos Med Assoc*. 2020; **119**(7): 1180–4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Zhong ZF, Huang J, Yang X, et al.: **Epidemiological and clinical characteristics of COVID-19 patients in Hengyang, Hunan Province, China**. *World J Clin Cases*. 2020; **8**(12): 2554–65.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Lu R, Qin J, Wu Y, et al.: **Epidemiological and clinical characteristics of COVID-19 patients in Nantong, China**. *J Infect Dev Ctries*. 2020; **14**(5): 440–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Liu L, Lei X, Xiao X, et al.: **Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyan City, China**. *Front Cell Infect Microbiol*. 2020; **10**: 284.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Wang R, Pan M, Zhang X, et al.: **Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China**. *Int J Infect Dis*. 2020; **95**: 421–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Jin X, Lian JS, Hu JH, et al.: **Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms**. *Gut*. 2020; **69**(6): 1002–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Lam HY, Lam TS, Wong CH, et al.: **The epidemiology of COVID-19 cases and the successful containment strategy in Hong Kong-January to May 2020**. *Int J Infect Dis*. 2020; **98**: 51–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Hu X, Xing Y, Jia J, et al.: **Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19**. *Sci Total Environ*. 2020; **728**: 138812.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Lu X, Gong W, Peng Z, et al.: **High Resolution CT Imaging Dynamic Follow-Up Study of Novel Coronavirus Pneumonia**. *Front Med (Lausanne)*. 2020; **7**: 168.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Li J, Chen Z, Nie Y, et al.: **Identification of Symptoms Prognostic of COVID-19 Severity: Multivariate Data Analysis of a Case Series in Henan Province**. *J Med Internet Res*. 2020; **22**(6): e19636.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Yin S, Peng Y, Ren Y, et al.: **The implications of preliminary screening and diagnosis: Clinical characteristics of 33 mild patients with SARS-CoV-2 infection in Hunan, China**. *J Clin Virol*. 2020; **128**: 104397.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Shao F, Xu S, Ma X, et al.: **In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China**. *Resuscitation*. 2020; **151**: 18–23.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Luo Y, Wu J, Lu J, et al.: **Investigation of COVID-19-related symptoms based on factor analysis**. *Ann Palliat Med*. 2020; **9**(4): 1851–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Mao L, Jin H, Wang M, et al.: **Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China**. *JAMA Neurol*. 2020; **77**(6): 683–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Liu L, Hong X, Su X, et al.: **Optimizing screening strategies for coronavirus disease 2019: A study from Middle China**. *J Infect Public Health*. 2020; **13**(6): 868–72.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Huang L, Zhang X, Zhang X, et al.: **Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16–23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study**. *J Infect*. 2020; **80**(6): e1–e13.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Wu Y, Feng Z, Li P, et al.: **Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19**. *Clin Chim Acta*. 2020; **509**: 220–3.  
[PubMed Abstract](#) | [Publisher Full Text](#)
92. He S, Zhou C, Lu D, et al.: **Relationship between chest CT manifestations and immune response in COVID-19 patients**. *Int J Infect Dis*. 2020; **98**: 125–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Zhao J, Gao HY, Feng ZY, et al.: **A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People's Hospital, Zhengzhou, China**. *Front Med (Lausanne)*. 2020; **7**: 286.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Yao Q, Wang P, Wang X, et al.: **A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients**. *Pol Arch Intern Med*. 2020; **130**(5): 390–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Zhang J, Wang X, Jia X, et al.: **Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China**. *Clin Microbiol Infect*. 2020; **26**(6): 767–72.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Hou H, Zhang B, Huang H, et al.: **Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19**. *Clin Exp Immunol*. 2020; **201**(1): 76–84.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Ghweil AA, Hassan MH, Khodeary A, et al.: **Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample of ESNA Quarantine Hospital's Patients, Egypt: A Retrospective Study**. *Infect Drug Resist*. 2020; **13**: 2375–83.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Lapostolle F, Schneider E, Vianu I, et al.: **Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study**. *Intern Emerg Med*. 2020; **15**(5): 813–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Zayet S, Kadiane-Oussou N, Lepiller Q, et al.: **Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster**. *Microbes Infect*. 2020. **22**(9): 481–488.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Poncet-Megemont L, Paris P, Tronchere A, et al.: **High Prevalence of Headaches During Covid-19 Infection: A Retrospective Cohort Study**. *Headache*. 2020.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Kremer S, Lersy F, Anheim M, et al.: **Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study**. *Neurology*. 2020; **95**(13): e1868–e1882.  
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Rokohl AC, Loreck N, Wawer Matos PA, et al.: **More than loss of taste and smell: burning watering eyes in coronavirus disease 2019**. *Clin Microbiol Infect*. 2020; **S1198-743X(20)30501-2**.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Bhandari S, Singh A, Sharma R, et al.: **Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study**. *J Assoc Physicians India*. 2020; **68**(6): 13–9.  
[PubMed Abstract](#)
104. Gupta N, Agrawal S, Ish P, et al.: **Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India**. *Monaldi Arch Chest Dis*. 2020; **90**(1).  
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Luigetti M, Iorio R, Bentivoglio AR, et al.: **Assessment of neurological manifestations in hospitalized patients with COVID-19**. *Eur J Neurol*. 2020; **27**(11): 2322–2328.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. d'Ettorre G, Ceccarelli G, Marazzato M, et al.: **Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19**. *Front Med (Lausanne)*. 2020; **7**: 389.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Vacchiano V, Riguzzi P, Volpi L, et al.: **Early neurological manifestations of hospitalized COVID-19 patients**. *Neural Sci*. 2020; **41**(8): 2029–31.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. Musolino AM, Supino MC, Buonsenso D, et al.: **Lung Ultrasound in Children with COVID-19: Preliminary Findings**. *Ultrasound Med Biol*. 2020; **46**(8): 2094–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Vaira LA, Deiana G, Fois AG, et al.: **Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases**. *Head Neck*. 2020; **42**(6): 1252–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. D'Ascanio L, Pandolfini M, Cingolani C, et al.: **Olfactory Dysfunction in COVID-19 Patients: Prevalence and Prognosis for Recovering Sense of Smell**. *Otolaryngol Head Neck Surg*. 2020; **194599820943530**.  
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Gelardi M, Trecca E, Cassano M, et al.: **Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report**. *Acta Biomed*. 2020; **91**(2): 230–1.  
[PubMed Abstract](#) | [Free Full Text](#)
112. Nakagawara K, Masaki K, Uwamino Y, et al.: **Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections**. *Int J Infect Dis*. 2020; **99**: 19–22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Miyamae Y, Hayashi T, Yonezawa H, et al.: **Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan**. *Int J Infect Dis*. 2020; **97**: 293–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Samrah SM, Al-Mistarehi AHW, Ibban AM, et al.: **COVID-19 outbreak in Jordan: Epidemiological features, clinical characteristics, and laboratory findings**. *Ann Med Surg (Lond)*. 2020; **57**: 103–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Farah Yusuf Mohamud M, Garad Mohamed Y, Mohamed Ali A, et al.: **Loss of Taste and Smell are Common Clinical Characteristics of Patients with COVID-19 in Somalia: A Retrospective Double Centre Study**. *Infect Drug*

- Resist.* 2020; **13**: 2631–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Kim GU, Kim MJ, Ra SH, et al.: **Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19.** *Clin Microbiol Infect.* 2020; **26**(7): 948.e1–e3.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
117. Lee JY, Hong SW, Hyun M, et al.: **Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea.** *Int J Infect Dis.* 2020; **98**: 462–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Trigo J, Garcia-Azorin D, Planchuelo-Gomez A, et al.: **Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study.** *J Headache Pain.* 2020; **21**(1): 94.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Garcia-Azorin D, Trigo J, Talavera B, et al.: **Frequency and Type of Red Flags in Patients With Covid-19 and Headache: A Series of 104 Hospitalized Patients.** *Headache.* 2020.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Calica Utku A, Budak G, Karabay O, et al.: **Main symptoms in patients presenting in the COVID-19 period.** *Scott Med J.* 2020; **65**(4): 127–132.  
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Karadas O, Ozturk B, Sonkaya AR: **A prospective clinical study of detailed neurological manifestations in patients with COVID-19.** *Neurol Sci.* 2020; **41**(8): 1991–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Yan CH, Faraji F, Prajapati DP, et al.: **Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms.** *Int Forum Allergy Rhinol.* 2020; **10**(7): 806–13.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Ellington S, Strid P, Tong VT, et al.: **Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020.** *MMWR Morb Mortal Wkly Rep.* 2020; **69**(25): 769–75.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Corsini Campioli C, Cano Cevallos E, Assi M, et al.: **Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19.** *J Clin Virol.* 2020; **130**: 104577.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Bergquist SH, Partin C, Roberts DL, et al.: **Non-hospitalized Adults with COVID-19 Differ Noticeably from Hospitalized Adults in Their Demographic, Clinical, and Social Characteristics.** *SN Compr Clin Med.* 2020; 1–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
126. Palaodimos L, Kokkinidis DG, Li W, et al.: **Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York.** *Metabolism.* 2020; **108**: 154262.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Ibrahim LF, Tosif S, McNab S, et al.: **SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital.** *Emerg Med Australas.* 2020; **32**(5): 801–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
128. Lam RPK, Hung KKC, Lau EHY, et al.: **Clinical, laboratory, and radiological features indicative of novel coronavirus disease (COVID-19) in emergency departments - a multicentre case-control study in Hong Kong.** *J Am Coll Emerg Physicians Open.* 2020; **1**(4): 597–608.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Mizrahi B, Shilo S, Rossman H, et al.: **Longitudinal symptom dynamics of COVID-19 infection in primary care.** *medRxiv.* 2020.  
[Publisher Full Text](#)
130. La Torre G, Massetti AP, Antonelli G, et al.: **Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study.** *J Clin Med.* 2020; **9**(9): 2870.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Fistera D, Pabst D, Hartl A, et al.: **Separating the wheat from the chaff-COVID-19 in a German emergency department: a case-control study.** *Int J Emerg Med.* 2020; **13**(1): 44.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
132. Caturegli G, Mater J, Howard BM, et al.: **Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case-Control Study.** *Ann Intern Med.* 2020; **173**(8): 614–622.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
133. Roland LT, Gurrola PA 2nd, Loftus PA, et al.: **Smell and taste symptom-based predictive model for COVID-19 diagnosis.** *Int Forum Allergy Rhinol.* 2020; **10**(7): 832–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. Yan G, Lee CK, Lam LTM, et al.: **Covert COVID-19 and false-positive dengue serology in Singapore.** *Lancet Infect Dis.* 2020; **20**(5): 536.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
135. Correia AO, Feitosa PWG, Moreira JLS, et al.: **Neurological manifestations of COVID-19 and other coronaviruses: A systematic review.** *Neurol Psychiatry Brain Res.* 2020; **37**: 27–32.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Shehata MM, Gomaa MR, Ali MA, et al.: **Middle East respiratory syndrome coronavirus: a comprehensive review.** *Front Med.* 2016; **10**(2): 120–36.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. Bolay H, Gül A, Baykan B: **COVID-19 is a Real Headache!** *Headache.* 2020.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
138. Ong JY, Bharatendu C, Goh Y, et al.: **Headaches Associated With Personal Protective Equipment - A Cross-Sectional Study Among Frontline Healthcare Workers During COVID-19.** *Headache.* 2020; **60**(5): 864–77.  
[PubMed Abstract](#) | [Publisher Full Text](#)
139. Porta-Etessam J, Matias-Guiu JA, Gonzalez-Garcia N, et al.: **Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.** *Headache.* 2020.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Gatti F, Manneschi L: **Headache relevance in outpatient activity during COVID-19 pandemic.** *Neural Sci.* 2020; 1–2.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Dodick DW: **A Phase-by-Phase Review of Migraine Pathophysiology.** *Headache.* 2018; **58** Suppl 1: 4–16.  
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Edvinsson JCA, Viganò A, Alekseeva A, et al.: **The fifth cranial nerve in headaches.** *J Headache Pain.* 2020; **21**(1): 65.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Goadsby PJ, Holland PR, Martins-Oliveira M, et al.: **Pathophysiology of Migraine: A Disorder of Sensory Processing.** *Physiol Rev.* 2017; **97**(2): 553–622.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
144. Mayberg MR, Zervas NT, Moskowitz MA: **Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry.** *J Comp Neurol.* 1984; **223**(1): 46–56.  
[PubMed Abstract](#) | [Publisher Full Text](#)
145. Schoonman GG, van der Grond J, Kortmann C, et al.: **Migraine headache is not associated with cerebral or meningeal vasodilatation—a 3T magnetic resonance angiography study.** *Brain.* 2008; **131**(Pt 8): 2192–200.  
[PubMed Abstract](#) | [Publisher Full Text](#)
146. Akerman S, Holland PR, Goadsby PJ: **Diencephalic and brainstem mechanisms in migraine.** *Nat Rev Neurosci.* 2011; **12**(10): 570–84.  
[PubMed Abstract](#) | [Publisher Full Text](#)
147. Messlinger K: **The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system.** *J Headache Pain.* 2018; **19**(1): 22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Bista P, Imlach WL: **Pathological Mechanisms and Therapeutic Targets for Trigeminal Neuropathic Pain.** *Medicines (Basel).* 2019; **6**(3): 91.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Takeda M, Tanimoto T, Matsumoto S: **Change in mechanical receptive field properties induced by GABA(A) receptor activation in the trigeminal spinal nucleus caudalis neurons in rats.** *Exp Brain Res.* 2000; **134**(4): 409–16.  
[PubMed Abstract](#) | [Publisher Full Text](#)
150. de Vries T, Villalón CM, MaassenVanDenBrink A: **Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.** *Pharmacol Ther.* 2020; **211**: 107528.  
[PubMed Abstract](#) | [Publisher Full Text](#)
151. Villalón CM, VanDenBrink AM: **The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.** *Mini Rev Med Chem.* 2017; **17**(11): 928–38.  
[PubMed Abstract](#) | [Publisher Full Text](#)
152. Imboden H, Patil J, Nussberger J, et al.: **Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia.** *Regul Pept.* 2009; **154**(1–3): 23–31.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
153. Portaluppi F, Vergnani L, Margutti A, et al.: **Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man.** *J Clin Endocrinol Metab.* 1993; **77**(3): 816–20.  
[PubMed Abstract](#) | [Publisher Full Text](#)
154. Agyeman AA, Chin KL, Landersdorfer CB, et al.: **Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis.** *Mayo Clin Proc.* 2020; **95**(8): 1621–31.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
155. Eliezer M, Hautefort C, Hamel AL, et al.: **Sudden and Complete Olfactory Loss of Function as a Possible Symptom of COVID-19.** *JAMA Otolaryngol Head Neck Surg.* 2020; **146**(7): 674–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
156. Xydakis MS, Dehghani-Mobaraki P, Holbrook EH, et al.: **Smell and taste dysfunction in patients with COVID-19.** *Lancet Infect Dis.* 2020; **20**(9): 1015–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
157. Perlman S, Jacobsen G, Afifi A: **Spread of a neurotropic murine coronavirus into the CNS via the trigeminal and olfactory nerves.** *Virology.* 1989; **170**(2): 556–60.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
158. Brand G: **Olfactory/trigeminal interactions in nasal chemoreception.** *Neurosci Biobehav Rev.* 2006; **30**(7): 908–17.  
[PubMed Abstract](#) | [Publisher Full Text](#)
159. Schaefer ML, Böttger B, Silver WL, et al.: **Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli.** *J Comp Neurol.* 2002; **444**(3):

- 221–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
160. Miranda-Saksena M, Denes CE, Diefenbach RJ, *et al.*: **Infection and Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton.** *Viruses*. 2018; **10**(2): 92.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
161. Merino-Gracia J, García-Mayoral MF, Rodríguez-Crespo I: **The association of viral proteins with host cell dynein components during virus infection.** *FEBS J*. 2011; **278**(17): 2997–3011.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. St-Jean JR, Jacomy H, Desforages M, *et al.*: **Human respiratory coronavirus OC43: genetic stability and neuroinvasion.** *J Virol*. 2004; **78**(16): 8824–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
163. Alvarez E, DeDiego ML, Nieto-Torres JL, *et al.*: **The envelope protein of severe acute respiratory syndrome coronavirus interacts with the non-structural protein 3 and is ubiquitinated.** *Virology*. 2010; **402**(2): 281–91.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Bearer EL, Breakefield XO, Schuback D, *et al.*: **Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument.** *Proc Natl Acad Sci U S A*. 2000; **97**(14): 8146–50.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
165. Antinone SE, Smith GA: **Retrograde axon transport of herpes simplex virus and pseudorabies virus: a live-cell comparative analysis.** *J Virol*. 2010; **84**(3): 1504–12.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
166. Bohmwald K, Gálvez NMS, Ríos M, *et al.*: **Neurologic Alterations Due to Respiratory Virus Infections.** *Front Cell Neurosci*. 2018; **12**: 386.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
167. Grigoryan S, Kinchington PR, Yang IH, *et al.*: **Retrograde axonal transport of VZV: kinetic studies in hESC-derived neurons.** *J Neurovirol*. 2012; **18**(6): 462–70.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
168. Hunsperger EA, Roehrig JT: **Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice.** *J Neurovirol*. 2006; **12**(2): 129–39.  
[PubMed Abstract](#) | [Publisher Full Text](#)
169. Ugolini G: **Rabies virus as a transneuronal tracer of neuronal connections.** *Adv Virus Res*. 2011; **79**: 165–202.  
[PubMed Abstract](#) | [Publisher Full Text](#)
170. Huang C, Wang Y, Li X, *et al.*: **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet*. 2020; **395**(10223): 497–506.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
171. Mehta P, McAuley DF, Brown M, *et al.*: **COVID-19: consider cytokine storm syndromes and immunosuppression.** *Lancet*. 2020; **395**(10229): 1033–4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
172. Belvis R: **Headaches During COVID-19: My Clinical Case and Review of the Literature.** *Headache*. 2020; **60**(7): 1422–1426.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
173. Singh J, Ali A: **Headache as the Presenting Symptom in 2 Patients With COVID-19 and a History of Migraine: 2 Case Reports.** *Headache*. 2020; **60**(8): 1773–1776.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
174. Afroz S, Arakaki R, Iwasa T, *et al.*: **CGRP Induces Differential Regulation of Cytokines from Satellite Glial Cells in Trigeminal Ganglia and Orofacial Nociception.** *Int J Mol Sci*. 2019; **20**(3): 711.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
175. Kristiansen KA, Edvinsson L: **Neurogenic inflammation: a study of rat trigeminal ganglion.** *J Headache Pain*. 2010; **11**(6): 485–95.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
176. Neeb L, Hellen P, Hoffmann J, *et al.*: **Methylprednisolone blocks interleukin 1 beta induced calcitonin gene related peptide release in trigeminal ganglia cells.** *J Headache Pain*. 2016; **17**(1): 19.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
177. Edvinsson L, Haanes KA, Warfvinge K: **Does inflammation have a role in migraine?** *Nat Rev Neurol*. 2019; **15**(8): 483–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
178. Varga Z, Flammer AJ, Steiger P, *et al.*: **Endothelial cell infection and endotheliitis in COVID-19.** *Lancet*. 2020; **395**(10234): 1417–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
179. Hikmet F, Méar L, Edvinsson A, *et al.*: **The protein expression profile of ACE2 in human tissues.** *Mol Syst Biol*. 2020; **16**(7): e9610.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
180. de Moraes PL, Kangussu LM, Castro CH, *et al.*: **Vasodilator Effect of Angiotensin-(1-7) on Vascular Coronary Bed of Rats: Role of Mas, ACE and ACE2.** *Protein Pept Lett*. 2017; **24**(9): 869–75.  
[PubMed Abstract](#) | [Publisher Full Text](#)
181. Forte BL, Slosky LM, Zhang H, *et al.*: **Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.** *Pain*. 2016; **157**(12): 2709–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
182. Rabelo LA, Alenina N, Bader M: **ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease.** *Hypertens Res*. 2011; **34**(2): 154–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
183. Abboud H, Abboud FZ, Kharbouch H, *et al.*: **COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.** *World Neurosurg*. 2020; **140**: 49–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
184. Olesen J, Friberg L, Olsen TS, *et al.*: **Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults.** *Brain*. 1993; **116**(Pt 1): 187–202.  
[PubMed Abstract](#) | [Publisher Full Text](#)
185. Eccles R: **Understanding the symptoms of the common cold and influenza.** *Lancet Infect Dis*. 2005; **5**(11): 718–25.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
186. Nicholson KG: **Clinical features of influenza.** *Semin Respir Infect*. 1992; **7**(1): 26–37.  
[PubMed Abstract](#)
187. Smith RS: **The cytokine theory of headache.** *Med Hypotheses*. 1992; **39**(2): 168–74.  
[PubMed Abstract](#) | [Publisher Full Text](#)
188. de Abreu LV, Oliveira CB, Bordini CA, *et al.*: **New Daily Persistent Headache Following Dengue Fever: Report of Three Cases and an Epidemiological Study.** *Headache*. 2020; **60**(1): 265–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
189. Harapan H: **Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis.** *figshare*. Figure. 2020.  
<http://www.doi.org/10.6084/m9.figshare.13166783.v1>

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 14 April 2021

<https://doi.org/10.5256/f1000research.55021.r81184>

© 2021 Nelwan E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Erni J. Nelwan** 

<sup>1</sup> Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Medical Faculty, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

<sup>2</sup> Infectious Diseases and Immunology Research Cluster, Faculty of Medicine, Universitas Indonesia, Depok City, Indonesia

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however, I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 11 March 2021

<https://doi.org/10.5256/f1000research.55021.r81183>

© 2021 Arab-Zozani M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Morteza Arab-Zozani** 

Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran

Thank you for modifying your paper and clearly addressing my comments. In my opinion, the manuscript is acceptable.

Cheers



**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Health Policy and Management, an expert in systematic review and meta-analysis methodology.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

### Version 1

Reviewer Report 15 February 2021

<https://doi.org/10.5256/f1000research.30205.r79512>

© 2021 Arab-Zozani M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Morteza Arab-Zozani**

Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran

Thank you for considering a great area of interest related to COVID-19. This study aimed to investigate the prevalence and pathogenesis of headache in COVID-19 patients, globally. The methodology is completely rigorous and the results are interesting. I have a few minor comments to the authors as follow:

- In the study selection and/or quality appraisal stages are the authors faced with discrepancies? Please state how resolved these potential discrepancies.
- Was it not possible to analyze the subgroups? For example, based on age groups or gender.
- Please add some details about the NOS checklist and also add the result of the quality appraisal to the manuscript.

**Are the rationale for, and objectives of, the Systematic Review clearly stated?**

Yes

**Are sufficient details of the methods and analysis provided to allow replication by others?**

Yes

**Is the statistical analysis and its interpretation appropriate?**

Yes

**Are the conclusions drawn adequately supported by the results presented in the review?**



Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Health Policy and Management, an expert in systematic review and meta-analysis methodology.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 26 Feb 2021

**Endang Mutiawati**, Universitas Syiah Kuala, Banda Aceh, Indonesia

Dear Dr Morteza Arab-Zozani,

Thank you for your comments.

1. We have provide the approach how to solve in case there was discrepancies between two authors during evaluation of the studies.

2. We were unable to do sub-group analysis based on age and gender due to available of data. We have added this as one of our limitation: We have added this in our manuscript: "In this analysis we did not analyze the prevalence of headache based on COVID-19 severity, the existence of COVID-19 co-morbidity (such as diabetes and hypertension) and based on demographic characteristics such as gender due to scarcity of the available data. Therefore, whenever enough data are available, such sub-analyses are critical to be conducted."

3. We have provide more detail information of Newcastle-Ottawa scale (NOS) - What items that were assessed and how to score as well how the studies classified. We also have added the NOS scores briefly to all studies included in the study.

Thank you

**Competing Interests:** I do not have conflict of interest.

Reviewer Report 04 December 2020

<https://doi.org/10.5256/f1000research.30205.r74699>

© 2020 Nelwan E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Erni J. Nelwan** 

<sup>1</sup> Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Medical Faculty, Cipto Mangunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia

<sup>2</sup> Infectious Diseases and Immunology Research Cluster, Faculty of Medicine, Universitas Indonesia, Depok City, Indonesia

Authors seem not considered potential important bias while choosing headaches to be analysed. While among patients with fever (mainly), headache is in the same pathophysiology response due to prostaglandin release. Not to include other symptoms, so it is not merely a headache as a symptom.

How about the existence of co-morbidity such as Hypertension (uncontrolled hypertension)? It is not clear how to justify data with such condition concomitantly.

In the results section, what does this statement mean?

"Headache was found to be more prevalent, approximately by two-fold, in COVID-19 patients than in non-COVID-19 patients with symptoms of other respiratory viral infections, OR: 1.73; 95% CI: 1.94, 2.5 with p=0.04."

What kind of non-covid-19 patients with symptoms of other respiratory viral infections? This is a confusing statement.

As a clinician taking care of Covid-19 patients, the importance of this article is low.

**Are the rationale for, and objectives of, the Systematic Review clearly stated?**

Partly

**Are sufficient details of the methods and analysis provided to allow replication by others?**

No

**Is the statistical analysis and its interpretation appropriate?**

I cannot comment. A qualified statistician is required.

**Are the conclusions drawn adequately supported by the results presented in the review?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** infectious disease

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 26 Feb 2021

**Endang Mutiawati**, Universitas Syiah Kuala, Banda Aceh, Indonesia

Dear Dr Erni J. Nelwan

We agreed that our study have limitation since we did not able to analysed the data based on existence of COVID-19 co-morbidity. This is mainly because the available of data. The data was scarce.

We have added this in our manuscript: "In this analysis we did not analyze the prevalence of headache based on COVID-19 severity, the existence of COVID-19 co-morbidity (such as diabetes and hypertension) and based on demographic characteristics such as gender due to scarcity of the available data. Therefore, whenever enough data are available, such sub-analyses are critical to be conducted."

We have provided a clear explanation about the non-COVID-19 in Method section as requested. Not-COVID-19 in our study refers to other respiratory viral infections such as rhinovirus, influenza, parainfluenza and respiratory syncytial virus. We added: "non-COVID-19 cases (other respiratory viral infections such as rhinovirus, influenza, parainfluenza and respiratory syncytial virus)" in text.

We also also agreed that the pathogenesis of headache is complex including the production of prostaglandin while fever. Therefore in our study we compared the occurrence of headache in COVID-19 and other non-COVID-19 respiratory infection as control. This to reduce the effect of fever since in both COVID-19 and non-COVID-19 cases the fever are present. Due to this complexity we did not claim any diagnostic for direct clinical practice.

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**